J&J has initiated a global Phase III clinical trial to study JNJ-78436735, a vaccine candidate for the prevention of COVID-19.
List view / Grid view
Johnson & Johnson (J&J)
Filter the results
A new report has shown that through the COVID-19 pandemic, the global nasal drug delivery technology market is predicted to increase.
J&J has paused its Phase III trial for its COVID-19 vaccine candidate following an unexplained illness in a study participant.
J&J has agreed that it will supply the EU with 200 million doses of its COVID-19 vaccine candidate following regulatory approval.
US outsourcing organisation GRAM is set to undertake the aseptic fill and finish manufacture of J&J's COVID-19 vaccine candidate.
A Phase III clinical trial to evaluate J&J's COVID-19 vaccine in multiple countries has enrolled its first patients.
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
J&J will supply the US with 100 million doses of the company’s COVID-19 vaccine candidate following an agreement with the country's government.
The investigational SARS-CoV-2 vaccine developed by J&J is now due to start its Phase I/IIa clinical trial at the end of July.
Sergio Traversa, PharmD, from Relmada Therapeutics explains why NMDA antagonists may provide an answer for patients who do not respond to current antidepressant therapies.
FDA approves IMBRUVICA® (ibrutinib) for treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma
IMBRUVICA (ibrutinib), in combination with rituximab, has been given approval in the US for the treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
Following the selection of a COVID-19 vaccine lead, Johnson & Johnson (J&J) aims to begin clinical trials in humans later this year while also scaling up its manufacturing facilities.
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) was devised to create transformative regimens for TB treatment, irrespective of drug resistance status.
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.